Stoke Therapeutics, Inc. (STOK)

In other recent news, State Street ... core earnings per share of $2.84, surpassing both BofA Securities’ estimate and the consensus expectation of $2.64. The company’s net interest income was 7% above consensus, and its fee revenue exceeded estimates by 2%, although expenses were 2% higher than ant…

Stoke Therapeutics (STOK) is drawing investor attention after recent share price moves, with the stock roughly flat over the past day but down over the past week, month and past 3 months. See our latest analysis for Stoke Therapeutics. Zooming out, the recent soft 7 day and 90 day share price ...

Taken together, the convergence ... of the stock’s largest single-session moves since its Frankfurt IPO in October 2025. With shares trading at €94.50 — still below the 52-week high of €107 — investors appear to be pricing in a significant but not yet complete re-rating of the company’s long-term ea…

Samsung Electronics Stock Drops Below 290,000 Won Despite Earnings Miss Record revenue and profit fail to offset investor disappointment as semiconduc

PepsiCo (PEP) stock is facing caution from Wall Street after Barclays lowered its price target on the beverage and snacks giant ahead of its second-quarter earnings, reflecting growing concerns about the pace of recovery in the company’s North American fo